The Pharmatech, Inc. leadership team is instrumental in facilitating our operational roles and responsibilities to deliver quality research management services. The following management profiles provide an introduction to our leadership team.
Matthew Wiener is in his twentieth year as the Founder and Chief Scientific Officer of Pharmatech, Inc. Dr. Wiener is a clinical research pharmacist and has served on the faculties of Columbia College of Pharmaceutical Sciences and National Jewish Center for Immunology and Respiratory Medicine, and also held the directorship of a private practice research center.
In the capacity of CSO, he has diverse experience in the design and supervision of clinical research studies. Dr. Wiener has over 20 years of clinical research experience, and his novel recruitment and clinical trials management strategies make him a leader in his field.
Mr. Rob Bohacs joined Pharmatech, Inc. in 2007 as Director of Sales and Marketing. Since then, he has assumed greater responsibilities, yielding significant performance and operational efficiencies. Through an effective sales team, Mr. Bohacs has grown Pharmatech’s backlog of business nearly threefold, and has had a profound impact on the company’s commercialization of its oncology network and its Just-In-Time enrollment methodology.
Mr. Bohacs has a deep background in business operations, sales management and financial management. Prior to joining Pharmatech, Inc., he was a partner in a healthcare-focused private equity firm and managed a small healthcare product and service conglomerate company from inception through a successful acquisition. He is a graduate of the Graziadio School of Business and Management at Pepperdine University in Malibu, California, where he earned his MBA.
As CEO, Mr. Bohacs’ objective is to help pharmaceutical clients navigate the challenges and inefficiencies of the clinical trial process, as well as to help align the values of clinical trials with patients’ needs for greater cancer treatment options.
With twenty years of experience in cancer-related industries, Eric Lynam has taken part in many of the exciting research advances leading up to the age of personalized cancer medicine. His responsibilities include the development of new research opportunities, pre-study feasibility analysis, protocol development and scientific publications.
Dr. Alvin Beers is a board-certified medical oncologist who has been involved in research for his entire 35-year career. He has worked as a principal investigator for the Colorado Cancer Research Program and is a consultant to industry for cancer clinical trials. Dr. Beers brings to Pharmatech, Inc. an avid interest in promoting biomarkers in the diagnosis and treatment of malignant disease and a strong background in biochemistry.
As Pharmatech's Medical Director, Dr. Beers provides medical oversight, medical monitoring and clinical expertise to the Company.
Dr. Beers received his Doctorate from the University of Kansas School of Medicine and conducted his Fellowship in Hematology/Oncology at the University of Wisconsin.